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Abstract
Background: The choice of antiepileptic drug for an individual should be based upon the highest
quality evidence regarding potential benefits and harms of the available treatments. Systematic
reviews and meta-analysis of randomised controlled trials should be a major source of evidence
supporting this decision making process. We summarise all available individual patient data evidence
from randomised controlled trials that compared at least two out of eight antiepileptic drugs given
as monotherapy.
Methods: Multiple treatment comparisons from epilepsy monotherapy trials were synthesized in
a single stratified Cox regression model adjusted for treatment by epilepsy type interactions and
making use of direct and indirect evidence. Primary outcomes were time to treatment failure and
time to 12 month remission from seizures. A secondary outcome was time to first seizure.
Results: Individual patient data for 6418 patients from 20 randomised trials comparing eight
antiepileptic drugs were synthesized. For partial onset seizures (4628 (72%) patients), lamotrigine,
carbamazepine and oxcarbazepine provide the best combination of seizure control and treatment
failure. Lamotrigine is clinically superior to all other drugs for treatment failure but estimates
suggest a disadvantage compared to carbamazepine for time to 12 month remission [Hazard Ratio
(95% Confidence Interval) = 0.87(0.73 to 1.04)] and time to first seizure [1.29(1.13 to 1.48)].
Phenobarbitone may delay time to first seizure [0.77(0.61 to 0.96)] but at the expense of increased
treatment failure [1.60(1.22 to 2.10)]. For generalized onset tonic clonic seizures (1790 (28%)
patients) estimates suggest valproate or phenytoin may provide the best combination of seizure
control and treatment failure but some uncertainty remains about the relative effectiveness of
other drugs.
Conclusion: For patients with partial onset seizures, results favour carbamazepine, oxcarbazepine
and lamotrigine. For generalized onset tonic clonic seizures, results favour valproate and phenytoin.
Background
Epilepsy is a common neurological condition with a prev-
alence of around 0.5% and a life time incidence of around
3% [1]. The majority of people with epilepsy are treated
with a single (monotherapy) antiepileptic drug (AED),
and 60–70% of patients will enter a remission from sei-
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[2,3]. Current guidelines recommend valproate (VPA) as
a treatment of first choice for patients with generalized
onset seizures whilst carbamazepine (CBZ) is recom-
mended as the first line treatment for patients with partial
onset seizures [4,5]. However, with several AEDs to
choose between and a number of new drugs licensed and
introduced over the last decade and a half [6,7], it is essen-
tial to evaluate the effectiveness of these drugs against
each other in the best possible way. The choice of AED for
an individual should be based upon the highest quality
evidence regarding potential benefits and harms of the
available treatments. Systematic reviews and meta-analy-
sis of randomised controlled trials should be a major
source of evidence supporting this decision making proc-
ess.
Eight separate Cochrane systematic reviews with meta-
analysis have been prepared, or are in preparation, in
which the following AED comparisons are made: CBZ
against VPA [8], phenytoin (PHT) against VPA [9], CBZ
against PHT [10], PHT against phenobarbitone (PB) [11],
CBZ against PB [12], VPA against PB (review in prepara-
tion), oxcarbazepine (OXC) against PHT [13] and lamot-
rigine (LTG) against CBZ [14]. An individual patient data
(IPD) approach using full original trial data sets rather
than published or aggregate level data, has been used in
these reviews, an approach that is regarded as the gold
standard for meta-analysis [15]. Each Cochrane review
provides the best available evidence about the compara-
tive effects of each pair of drugs (pair-wise direct compar-
ison). However, in isolation, each pair-wise comparison
does not inform a choice among all these drugs and inter-
pretation of the complete evidence base can be difficult
for the physician or patient. Further difficulties arise with
this current evidence base since direct evidence is not
available for some pair-wise comparisons. For example,
evidence directly comparing OXC with LTG or PB does
not currently exist from a randomised controlled trial and,
for OXC compared to PB, is unlikely to be examined in
future trials because of changes in 'fashions' for treatment.
Meta-analyses of randomised controlled trials tradition-
ally focus on the pair-wise comparison between two treat-
ments, say A and B, with each included trial providing
information for the direct comparison between A and B.
For some treatment comparisons, randomised controlled
trials may not exist therefore the treatment effect cannot
be directly estimated. However, it is possible to estimate
the indirect treatment effect of A versus B using evidence
from trials comparing drug A with C, and trials comparing
drug B with C. The key assumption for the indirect com-
parison is one of exchangeability of the treatment effect
across all included trials such that the effect of A versus B
would be expected to be similar if estimated within the tri-
als that actually did compare A versus B or likewise within
the trials that only compared B versus C. This assumption
may be reasonable if the trial setting and clinical charac-
teristics are similar or if any differences between trials
would not be expected to modify the relative treatment
effects. Although no formal statistical test exists to exam-
ine this assumption, careful consideration should be
given for the reliability of this assumption.
Indirect comparisons can be valuable in situations partic-
ularly where direct comparisons either do not exist, com-
prise a limited amount of data, or are unlikely to ever be
examined in future trials. Methods for estimating an indi-
rect comparison using aggregate data have been discussed
previously [16] and compared to direct evidence across 44
systematic reviews by Song et al [17]. They concluded that
indirect comparisons usually (but not always) agree with
the results of direct randomised trials with their validity
dependent upon the internal validity and similarity of the
included trials.
In this paper we describe a simultaneous analysis of IPD
from randomised controlled trials included across the
eight original Cochrane reviews along with subsequently
obtained IPD from the largest ever randomised trial in
epilepsy patients [6,7]. These randomised trials contribute
direct and indirect evidence for multiple treatment com-
parisons of eight different AEDs that have a license for use
as monotherapy in at least one country and will provide
the best available overall summary of their comparative
effects. This analysis will aid an evidence-based decision
making process and simplify interpretation of the evi-
dence for the physician and patient. The approach could
be expanded to incorporate data for other AEDs once
available, and the methods are relevant to many other
areas of medicine where choices have to be made among
a number of treatment options.
There is increasing recognition of a need to use multiple
treatment comparisons with direct and indirect evidence
to inform healthcare decisions [18] and it appears the log-
ical next step following individual pair-wise meta-analy-
ses. To our knowledge, this is the first such analysis based
on IPD which is recognised to be the gold standard
approach both in pair-wise meta-analyses and therefore,
we believe, for multiple treatment comparison analyses.
Methods
IPD reviews
Each Cochrane systematic review of epilepsy mono-
therapy trials used identical protocol and review method-
ology. The search strategy included searching Medline
1966–2006 using the Cochrane Epilepsy Groups compre-
hensive search strategy, the Cochrane Controlled Trials
Register and the Cochrane Epilepsy Group's register ofPage 2 of 10
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included if they were double (patient and clinician), sin-
gle (patient or clinician) or unblinded randomised con-
trolled trials in which the two treatments of interest in the
particular review were compared directly. Trial partici-
pants were children or adults with a new diagnosis of epi-
lepsy, or a relapse following AED withdrawal, or who had
failed on other therapies. Patients' seizures were classified
as either partial onset (simple partial, complex partial, or
secondarily generalising tonic-clonic seizures) or as gener-
alised onset tonic-clonic seizures. Trials recruiting patients
with other generalized seizure types (primarily absence
and Myoclonic seizures) in the absence of tonic clonic sei-
zures were excluded. All of the trials included in the
review were undertaken after the publication of the 1981
International League Against Epilepsy (ILAE) classifica-
tion of epileptic seizures [19], in which the distinction
between partial onset and generalized onset seizures is
made, hence patients could be split into partial onset and
generalized onset seizure subgroups. However, many of
the studies were initiated prior to the 1989 ILAE classifica-
tion of epileptic syndromes [20]; hence individual epi-
lepsy syndromes could not be investigated.
Three time-to-event outcomes were investigated, which
are those recommended by the ILAE [20]. The primary
outcomes were (i) time to treatment failure due to inade-
quate seizure control, intolerable adverse effects or a com-
bination of both; a combined outcome reflecting both
efficacy and tolerability and an outcome to which the
individual makes a contribution, and (ii) time to 12
month remission from seizures, defined as the number of
days between randomisation and end of a period of 12
months without seizures. A secondary outcome was time
to first seizure after randomisation. Further details regard-
ing specific review methodology are described in the rele-
vant review publication.
SANAD data
SANAD (A RCT Of Longer-Term Clinical Outcomes And
Cost Effectiveness Of Standard And New Antiepileptic
Drugs) was an unblinded randomized controlled trial
recruiting patients between January 1999 and August
2004. Arm A [6] recruited patients for whom CBZ was
considered to be standard treatment and they were rand-
omized to CBZ, gabapentin (GBP), LTG, OXC or topiram-
ate (TPM). Arm B [7] recruited patients for whom VPA was
considered to be standard treatment and they were rand-
omized to VPA, LTG, or TPM. Clinicians were asked to
classify seizures and epilepsy syndromes by ILAE classifi-
cations as far as was possible, at least to differentiate
between partial onset (focal) or generalised onset sei-
zures. Primary outcomes were time to treatment failure,
and time to 12 month remission. Secondary outcomes
included time to first seizure. IPD are available for all par-
ticipants.
Simultaneous analysis of multiple treatment comparison
All analyses are by intention to treat as far as possible. As
time to event outcomes are of interest, three Cox propor-
tional hazards models are fitted to the data, one model for
each outcome. To preserve the advantages of randomisa-
tion within each trial, the Cox model is stratified by trial
including all patients from all treatment groups in all tri-
als for which data are available [21]. The eight AEDs (CBZ,
VPA, PHT, PB, OXC, GBP, TPM and LTG) of interest may
be represented in the Cox proportional hazards model by
seven dummy variables. Estimates of the hazard ratio and
its standard error for each pair-wise comparison may be
obtained from this model with appropriate recognition of
the covariance between regression coefficients. With 8
AEDs, there are 28 possible pair-wise comparisons. For
ease of presentation, we present hazard ratio estimates for
each drug compared to the current standard (CBZ for par-
tial and VPA for generalised) in this paper. However, esti-
mates for all pair-wise comparisons were examined for
conclusions and are displayed in Figure X [see additional
file 1]. Further details regarding the model, model fit and
calculation of hazard ratios and confidence intervals are
given in Appendix 1 and discussed in more detail by
Tudur Smith [22].
Exchangeability
The assumption of exchangeability implies that the haz-
ard ratio for each treatment comparison is similar across
all covariate values i.e. there are no treatment by covariate
interactions. This assumption is clinically unlikely for the
epilepsy monotherapy comparisons since there are strong
prior beliefs that some AEDs have different effects for gen-
eralised and partial onset seizures, i.e. there is a treatment
by seizure type (partial versus generalized onset) interac-
tion. For example, VPA is considered the treatment of
choice for generalized seizures and epilepsy syndromes
and CBZ the treatment of choice for partial seizures and
epilepsy syndrome [23]. The availability of IPD for this
particular example enables analyses that adjust for the
effect of epilepsy type and interactions with treatments to
improve the application of results to specific patient pop-
ulations. This is achieved in the analysis by including
terms to represent the main effects of treatment and epi-
lepsy type and their interaction in the Cox model.
One further concern is that the individual trial data may
not necessarily be contemporaneous. In particular, data
for PB comes from trials that recruited patients between
1978 and 1987 whereas data for LTG comes from trials
that recruited between 1989 and 2004. Both drugs have
been compared against CBZ for which we have data across
the period between 1978 and 2004. The assumption ofPage 3 of 10
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CBZ, as estimated by the trials recruiting between 1978
and 1987, would also be expected if trials had compared
PB and CBZ between 1989 and 2004. It is possible that
improvements in clinicians' understanding of how to use
CBZ could change over the time period between 1978 and
2004. For example, clinicians may be less tolerant of
known adverse effects or may alter their pattern of dose
escalation or maintenance dose. Such changes in practice
could improve outcome over time for patients on CBZ
which could invalidate the assumption of exchangeabil-
ity. This hypothesis is explored by adding year of ran-
domisation (as a categorical variable) for patients on CBZ
to a Cox regression model with know prognostic factors
(number seizures before randomisation and epilepsy
type).
Consistency
For each comparison where direct evidence is available,
internal consistency of the direct evidence is assessed by
visual inspection of confidence intervals for each trial haz-
ard ratio, along with a chi-square test for heterogeneity
and calculation of the I2 statistic [24] for partial and gen-
eralised seizures separately. Consistency between the
direct and combination of direct and indirect evidence is
assessed by visual comparison of the hazard ratio esti-
mates and 95% confidence intervals from each direct (sei-
zure type specific) comparison with the corresponding
combined result.
Results
IPD are available for at least one outcome for 6418
patients with epilepsy type data across 20 randomised
controlled trials [25-41]. There are 5817 patients [1552
(27%) generalised; 4265 (73%) partial] randomised
within 17 trials available for the analysis of time to treat-
ment failure, 4886 patients [1360 (28%) generalised;
3526 (72%) partial] from 14 trials for the analysis of time
to 12 month remission and 5724 patients [1765 (31%)
generalised; 3959 (69%) partial] from 19 trials for the
analysis of time to first seizure. The summary of character-
istics (Table 1) [see additional file 2] suggests clinical
comparability across included trials and adds further sup-
port to the clinical justification for combining evidence
from these multiple sources. A meaningful summary of
titration schedules could not be created due to the inade-
quacy of data in trial publications.
Analyses adjusted for treatment and epilepsy type main
effects and their interaction are displayed in Figures 1, 2,
3, 4, 5, 6 for each outcome based on the multiple treat-
ment comparisons analysis of all relevant trials for which
data are available. Each figure presents a hazard ratio and
95% confidence interval for every AED compared with the
current standard (CBZ for partials and VPA for general-
ised) ordered by size of effect. Each box represents a point
estimate of hazard ratio with the size of each box inversely
proportional to the width of the 95% confidence interval
for the relevant hazard ratio.
Partial onset seizures
4628 (72%) patients were classified as having partial
onset seizures, and results are presented in figures 1, 2, 3.
Time to 12 month remission for partial onset seizures (Haz-ard Ratio for eac  AED compared to standard CBZ)F gure 2
Time to 12 month remission for partial onset sei-
zures (Hazard Ratio for each AED compared to 
standard CBZ). CBZ: Carbamazepine, VPA: Sodium Val-
proate, PHT: Phenytoin, PB: Phenobarbitone, LTG: Lamot-
rigine, OXC: Oxcarbazepine, GBP: Gabapentine, TPM: 
Topirimate
Hazard Ratio (95% confidence interval)
0.5 1 2
GBP 1.38 (1.15, 1.67)
VPA 1.20 (1.01, 1.42)
TPM 1.19 (0.99, 1.43)
LTG 1.15 (0.96, 1.37)
PHT 1.15 (0.94, 1.41)
PB 1.01 (0.77, 1.31)
OXC 1.00 (0.82, 1.22)
HR>1 CBZ betterHR<1 CBZ worse
Time to treatment failure for partial onset seizures (Hazard Ratio f r each AED compared to standard CBZ)F gure 1
Time to treatment failure for partial onset seizures 
(Hazard Ratio for each AED compared to standard 
CBZ). CBZ: Carbamazepine, VPA: Sodium Valproate, 
PHT: Phenytoin, PB: Phenobarbitone, LTG: Lamotrigine, 
OXC: Oxcarbazepine, GBP: Gabapentine, TPM: Topiri-
mate
Hazard Ratio (95% confidence interval)
0.5 1 2 5
PB 1.60 (1.22, 2.10)
PHT 1.24 (0.98, 1.57)
GBP 1.16 (0.96, 1.41)
TPM 1.13 (0.93, 1.37)
VPA 1.00 (0.82, 1.24)
OXC 0.88 (0.69, 1.12)
LTG 0.70 (0.58, 0.83)
HR>1 CBZ betterHR<1 CBZ worsePage 4 of 10
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(Figure 1), LTG is the best drug (LTG is significantly better
than all other AEDs apart from OXC), and PB is the worst
drug. There is a non-significant trend to suggest that OXC
may be better than CBZ but insufficient evidence to differ-
entiate between CBZ and VPA. There are further non-sig-
nificant trends to suggest that CBZ may be better than
TPM, GBP and PHT with the lower limits of the 95% con-
fidence interval limits not reaching clinical significance.
For time to 12-month remission (Figure 2) CBZ is signifi-
cantly better than GBP and VPA. There are non-significant
Time to first seizure for generalised onset seizures (Hazard Ratio f r each AED c mpar d to standard VPA)F gure 6
Time to first seizure for generalised onset seizures 
(Hazard Ratio for each AED compared to standard 
VPA). CBZ: Carbamazepine, VPA: Sodium Valproate, 
PHT: Phenytoin, PB: Phenobarbitone, LTG: Lamotrigine, 
OXC: Oxcarbazepine, GBP: Gabapentine, TPM: Topiri-
mate
Hazard Ratio (95% confidence interval)
0.1 0.2 0.5 1 2 5 10
LTG 1.47 (1.20, 1.80)
OXC 1.32 (0.90, 1.94)
PB 1.28 (0.92, 1.77)
CBZ 1.21 (0.99, 1.47)
TPM 1.19 (0.94, 1.51)
GBP 1.11 (0.16, 7.90)
PHT 0.97 (0.77, 1.23)
HR>1 VPA betterHR<1 VPA worse
Time to treatment failure for generalised onset seizures (Hazard Ratio for each AED compared to standard VPA)F gure 4
Time to treatment failure for generalised onset sei-
zures (Hazard Ratio for each AED compared to 
standard VPA). CBZ: Carbamazepine, VPA: Sodium Val-
proate, PHT: Phenytoin, PB: Phenobarbitone, LTG: Lamot-
rigine, OXC: Oxcarbazepine, GBP: Gabapentine, TPM: 
Topirimate
Hazard Ratio (95% confidence interval)
0.2 0.5 1 2 5 10 100
PB 1.83 (1.07, 3.13)
TPM 1.74 (1.28, 2.36)
CBZ 1.45 (1.07, 1.96)
GBP 1.59 (0.22, 11.50)
OXC 1.50 (0.84, 2.68)
LTG 1.30 (0.97, 1.75)
PHT 1.03 (0.71, 1.51)
HR<1 VPA worse HR>1 VPA better 
Time to first seizure for partial onset seizures (Hazard Ratio for ach AED compared to standard CBZ)F gure 3
Time to first seizure for partial onset seizures (Haz-
ard Ratio for each AED compared to standard CBZ). 
CBZ: Carbamazepine, VPA: Sodium Valproate, PHT: 
Phenytoin, PB: Phenobarbitone, LTG: Lamotrigine, OXC: 
Oxcarbazepine, GBP: Gabapentine, TPM: Topirimate
Hazard Ratio (95% confidence interval)
0.5 1 2
GBP 1.35 (1.15, 1.59)
LTG 1.29 (1.13, 1.48)
VPA 1.23 (1.06, 1.41)
PHT 1.04 (0.88, 1.24)
TPM 1.00 (0.85, 1.18)
OXC 0.99 (0.83, 1.19)
PB 0.77 (0.61, 0.96)
HR>1 CBZ betterHR<1 CBZ worse
Time to 12 month remission for generalised onset seizures (Hazard Ratio for each AED c mpar d to standard VPA)F gure 5
Time to 12 month remission for generalised onset 
seizures (Hazard Ratio for each AED compared to 
standard VPA). CBZ: Carbamazepine, VPA: Sodium Val-
proate, PHT: Phenytoin, PB: Phenobarbitone, LTG: Lamot-
rigine, OXC: Oxcarbazepine, GBP: Gabapentine, TPM: 
Topirimate
Hazard Ratio (95% confidence interval)
0.01 0.1 0.2 0.5 1 2
LTG 1.41 (1.10, 1.80)
PB 1.28 (0.89, 1.84)
OXC 1.10 (0.73, 1.67)
TPM 1.09 (0.86, 1.37)
CBZ 1.00 (0.81, 1.22)
PHT 0.92 (0.72, 1.18)
GBP 0.26 (0.04, 1.86)
HR>1 VPA betterHR<1 VPA worsePage 5 of 10
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with lower limits to the 95% confidence intervals close to
1.0. There is insufficient evidence to conclude whether
there are differences between CBZ and OXC or PB with
wide confidence intervals that include clinically impor-
tant differences in both directions. For the secondary out-
come, time to first seizure (Figure 3), CBZ is significantly
better than VPA, LTG and GBP but there is insufficient evi-
dence to conclude whether there are differences between
CBZ and OXC, TPM or PHT with wide confidence inter-
vals that contain clinically important values. PB is signifi-
cantly better than CBZ for this outcome suggesting that PB
is the most effective drug for delaying a first seizure.
Generalized onset tonic clonic seizures
1790 (28%) patients were classified as having generalized
onset tonic clonic seizures.
Results for time to treatment failure (Figure 4) indicate a
significantly better outcome for individuals treated with
VPA compared to CBZ, TPM and PB. There is a non-signif-
icant trend to suggest that VPA may be better than OXC
and GBP but the confidence intervals are wide and
include clinically important hazard ratios in both direc-
tions. There is a further non-significant trend in favour of
VPA over LTG with a clinically non-significant lower limit
of the confidence interval. There is insufficient evidence to
differentiate between VPA and PHT with a wide confi-
dence interval that contains clinically important results
for both drugs. For 12 month remission (Figure 5), results
suggest that VPA is significantly better than LTG. As the
confidence intervals for the hazard ratio comparing each
other drug with VPA each contain unity and clinically
important values in both directions there is insufficient
evidence to differentiate amongst the drugs. For the sec-
ondary outcome, time to first seizure (Figure 6), VPA is
significantly better than LTG with non-significant trends
to favour VPA over TPM, CBZ, PB and OXC. There is insuf-
ficient evidence to differentiate between VPA and PHT or
GBP.
Exchangeability
Although the time to event differed significantly accord-
ing to year of recruitment, there was no systematic pattern
of increasing hazard ratio over time for the any of the
three outcomes. There is insufficient evidence to support
the hypothesis that the effectiveness of CBZ increases over
time and the assumption of exchangeability for this aspect
appears reasonable. Further details are available on
request from the first author.
Consistency
For partial seizures there is evidence of statistical heteroge-
neity (qualitative) within the direct evidence for compari-
sons between CBZ and PB (time to treatment failure I2 =
66% and time to 12 month remission I2 = 67%), CBZ and
VPA (time to first seizure I2 = 78%). For generalized sei-
zures there is evidence of statistical heterogeneity (quali-
tative with overlap of CIs) within the direct evidence for
comparisons between PHT and VPA (time to treatment
failure I2 = 63%) and CBZ and PHT (time to 12 month
remission I2 = 73%).
Where comparisons are possible, the combined analysis
(including all direct and indirect data) is consistent, in
terms of hazard ratio and 95% confidence interval, with
the direct evidence. However, for the comparison between
VPA and TPM (partial seizures), the direct evidence
(SANAD arm B with only 33 patients across the two
drugs) suggests that TPM is significantly better than VPA
(HR = 0.35; 95% CI = 0.15 to 0.80) for achieving a 12
month remission but there is insufficient evidence to dif-
ferentiate between the two drugs in the combined analysis
(HR = 1.00; 95% CI = 0.78 to 1.27). Further detail con-
cerning the assessment of inconsistency can be made
available from the authors.
For the comparison between CBZ and PB, the methodo-
logical quality of one included trial (Placencia 1993) was
thought to be the main source of heterogeneity. As a sen-
sitivity analysis, the combined multiple comparison anal-
ysis was undertaken excluding this particular trial. This
reduced heterogeneity for the direct comparison but had
minimal impact on interpretation and clinical conclu-
sions for the combined multiple comparison analysis. The
largest impact was seen for 12 month remission (partial
subgroup) for which PB was less favoured in the sensitiv-
ity analysis [HR 1.22(0.90 to 1.64) in favour of CBZ for
the sensitivity analysis compared to 1.01(0.77 to 1.31)].
Discussion
In this paper we provide an up to date summary of multi-
ple treatment comparisons from 20 randomised control-
led trials (6418 patients) regarding the comparative effects
of eight AEDs. The results represent the best available evi-
dence about the comparative effects of these drugs, which
will inform both clinical decision making and future
research. Such results have not been available until now
since no trial has, or is ever likely to compare all drugs
directly.
The majority of the data (4628 (72%) patients) is for
patients with partial onset seizures, and results favour
OXC, CBZ, and LTG for the best combination of tolerabil-
ity and seizure control, of which OXC and CBZ provide
the best seizure control and LTG best tolerability resulting
in a lower treatment failure rate.
A smaller number of patients classified as having general-
ized onset tonic-clonic seizures were recruited into thePage 6 of 10
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(28%)). Some patients were experiencing other seizure
types (absence or myoclonus) although data on these sei-
zure types were not collected for the majority of trials dur-
ing follow-up, hence seizure outcomes apply to
generalized onset tonic clonic seizures only. The age dis-
tribution of patients reveals that approximately 30% were
classified as having generalized seizures with onset over
the age of 30 years, which is unlikely. For these patients it
is likely that the randomizing clinician was unable to state
with confidence that the seizures were partial in onset,
and patients were therefore misclassified as generalized in
onset. The group classified as having generalized onset sei-
zures is therefore most likely to include some patients
with partial onset seizures. Our results indicate that VPA
has a lower treatment failure for all drugs except PHT. This
is significant for PB, TPM, CBZ, and non significant for
LTG, OXC and GBP. For time to 12 month remission
results indicate that VPA is significantly superior to LTG
and non-significantly superior to PB OXC and TPM, while
PHT is non-significantly to VPA. These results do not
refute current NICE guidelines that recommend VPA as a
treatment of choice.
The results for patients with generalized onset tonic-clonic
seizures are limited by the fact that fewer such patients
have been recruited into randomised controlled trials, and
that a significant number of patients classified as having
generalized onset seizures may have been misclassified.
Also, patients with an idiopathic generalized epilepsy may
experience absence or myoclonic seizures. Other than in
SANAD, these seizure types were not measured during fol-
low-up, hence we do not know whether the 12 month
remission rates here reflect an effect on generalized onset
tonic-clonic seizures only, or upon all generalized seizure
types. There is some uncontrolled evidence that PHT can
exacerbate absence or myoclonus, and if true would have
an important effect on measures of seizure remission were
all generalized seizure types assessed during follow-up.
Future trials must measure these shortfalls if they are to
provide reliable information about relative treatment
effects.
Previous meta-analyses have investigated individual pair-
wise comparisons, which in isolation fall short of inform-
ing clinical decisions when there are a greater number of
treatment options available. An advantage of the
approach presented here is that it has allowed the full
integration of evidence regarding eight AEDs and utilises
data from the most recent and largest ever randomised
controlled trial in epilepsy patients (SANAD). Analyses
were performed using IPD from each trial. This approach
allows the standardisation of outcome definition across
trials. In particular we were able to assess the outcome for
patients with either partial or generalized onset seizures
and investigate the evidence to support prior clinical
belief that for example CBZ is superior for partial onset
seizures whilst VPA is superior for generalized onset sei-
zures. A thorough examination of comparability of trial
characteristics and an investigation into whether the effec-
tiveness of CBZ had changed over time were also under-
taken. These analyses would have been severely limited
without IPD.
The key assumption made in the simultaneous analysis of
multiple treatment comparisons is that the hazard ratio
for one treatment compared with another would be the
same across the entire set of trials included in the model
[16] irrespective of whether those treatments were
included in a particular trial. Caldwell et al [18] suggest
that one way to question this assumption is to imagine all
trials had compared the same treatments and to judge
whether they are sufficiently similar to be combined in a
meta-analysis. Each of the trials included in our analysis
were assessed for eligibility into separate systematic
reviews which all adopted the same inclusion criteria and
review protocol and thus this decision had already been
reached. We would encourage researchers undertaking
multiple treatment comparisons to assess similarity of tri-
als in this very way by developing a simple protocol
describing trial eligibility criteria into the combined anal-
ysis as would be done in any properly conducted system-
atic review and meta-analysis for a single pair-wise
comparison. Clinically, the trials are sufficiently similar to
combine in a single analysis and justified further by the
absence of a possible change in effect of CBZ over time
and the lack of clinical belief of any contraindications to
any of the anti-epileptic drugs in the included trials. The
formulation of carbamazepine or valproate used is one
potential source of clinical heterogeneity that could not
be investigated due to lack of relevant data. Although the
evidence for differing formulations' impact on outcome is
limited, the controlled release formulation of car-
bamazepine or valproate may be associated with less
treatment withdrawals due to adverse effects.
For the direct results there was evidence of heterogeneity
amongst trial effects for a few comparisons for particular
outcomes. Such heterogeneity may potentially bring
about inconsistency between the direct and indirect evi-
dence and could lead to difficulties with interpretation of
the multiple treatment comparisons analysis. Consistency
of the evidence is difficult to explore for this complex
dataset. However, we generally found good consistency
between the direct and combined multiple treatment
comparisons results and found no systematic pattern of
over or under estimation. This observation is in keeping
with a previous study [17] that found the direction of dis-
crepancy between direct and indirect estimates to be
inconsistent. We did however find some evidence ofPage 7 of 10
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(time to 12 month remission). However, only one trial
with 33 patients provided direct evidence for this compar-
ison. Further work is required to extend the multiple treat-
ment comparisons IPD analysis presented to allow
incorporation of heterogeneity which is likely to lead to
increased confidence interval widths. This note of caution
should be kept in mind when examining the presented
results.
The simultaneous analysis of multiple treatment compar-
isons is increasingly more common in the medical litera-
ture with previous applications seen using aggregate
data[42,43]. Caldwell et al [18] comment that a unified,
coherent analysis can be achieved only by analysing the
entire collection of relevant randomised controlled trials
while respecting randomisation. They argue that rather
than asking whether analyses comparing multiple treat-
ments should be used routinely, it is more appropriate to
ask whether they can be avoided. Comparing multiple
treatments should be considered as the bedrock for deci-
sions when several treatments are available [18]. The use
of IPD, with its associated benefits, can only strengthen
such decision-making.
Conclusion
Implications for practice
For patients with partial onset seizures, results favour
OXC, CBZ and LTG as drugs of choice. It will be noted that
all these drugs have their primary mode of action as volt-
age dependent and use dependent blockers of Na+ chan-
nels. The data presented here support the current
guidelines recommending the use of VPA as drug of first
choice for generalized onset tonic-clonic seizures. How-
ever the potential teratogenicity of VPA should be consid-
ered for women of child bearing age.
Implications for research
The paucity of data for patients with generalized onset
tonic clonic seizures highlights the need for trials into
which such individuals are recruited. The problems with
classification that are highlighted should be addressed in
future trials in which systems should be used to check sei-
zure and epilepsy classification on the one hand, whilst
allowing clinicians to express their uncertainty about clas-
sification on the other. These analyses will be continually
updated as new data become available.
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Appendix 1. Model for the analysis of multiple 
treatment comparisons
For the simultaneous analysis of multiple comparisons
between eight AEDs, a Cox proportional hazards model
stratified by trial assuming fixed treatment effects was fit-
ted, where the hazard for the ith patient (i = 1,..., nj) in the
jth trial (j = 1,..., J) is given by
λij = λ0j(t)exp(β1x1ij + β2x2ij + β3x3ij + β4x4ij + β5x5ij)
where xk's are treatment indicator variables and βk are
regression coefficients.
For comparisons with the baseline drug (CBZ in this
example), the hazard ratio is given by  with 95%
confidence interval  for k = 1,..., 5.
For other pair wise comparisons between drugs repre-
sented by dummy variables xkij and xmij the hazard ratio is
given by  with standard error
The model can be adjusted for the effect of covariate and
treatment-by-covariate interaction terms by including rel-
evant dummy variables in the linear predictor.
exp( )β k
exp( . ( ))β βk kSE± ∗1 96
exp[( )]β βk m−
SE SE SEk m k m k m( ) ( ) ( ) cov( , )β β β β β β− = + − ∗2 2 2Page 8 of 10
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